AOD-9604 side effects by evidence tier: the pooled six-trial tolerability data from the oral Phase 1 and 2 programme, the GRAS and FDA positions, animal work, and the injectable-route gap.
AOD-9604 is a synthetic sixteen-amino-acid fragment of human growth hormone that Metabolic Pharmaceuticals developed as an oral anti-obesity drug and took through Phase 1 and Phase 2 trials in the early 2000s. As research peptides go it is unusually well characterised for tolerability: a company ran controlled trials in nearly a thousand people, the efficacy result was negative, and the safety result was pooled and published anyway. That record is real, and narrower than the way it is usually quoted.
This page separates controlled human data, animal work and uncontrolled self-report, and lists the gaps. It sits beside the AOD-9604 profile and the AOD-9604 research overview, which tells the development story; the comparison with HGH Fragment 176-191 explains why the same sequence is sold under two names. It is a research reference, not advice.
Stier, Vos and Kenley, Journal of Endocrinology and Metabolism (2013), pooled tolerability data from the six Metabolic Pharmaceuticals trials, roughly nine hundred participants. In every trial the peptide was an oral tablet, given once daily at doses reported from 1 mg to 30 mg, for up to twelve weeks; the largest, a Phase 2b in about three hundred obese adults, used 1 mg daily.
The pooled result reported:
The metabolic findings were the point. Intact growth hormone raises glucose, causes insulin resistance and drives IGF-1; the trials were designed to show that the fragment does not, and across the pooled dataset they did. The Phase 2b trial was well tolerated in the same twelve weeks in which it failed its primary weight-loss endpoint — which says the compound was tolerated by mouth for three months, not that it was safe in any other sense.
In 2014 a GRAS self-affirmation was reported for AOD-9604 as an ingredient in foods at low oral doses. That was a determination by a company-convened expert panel, not an FDA review or approval, and it concerned oral food use only. It is not a regulatory endorsement.
The controlled record is entirely oral, short and adult. It does not cover:
The published record supports one narrow statement — oral AOD-9604 at 1–30 mg daily was well tolerated for up to twelve weeks — and nothing broader.
The rodent studies from the Monash group and the company (Heffernan and colleagues, Endocrinology and International Journal of Obesity, 2001; Ng and colleagues, Hormone Research, 2000) reported no toxicity at the doses studied, roughly 0.25 to 2 mg/kg per day for two to three weeks by intraperitoneal injection or oral gavage. Glucose tolerance was not impaired, IGF-1 did not rise, and the lipolytic effect persisted in β3-adrenergic-receptor knockout mice. Kwon and Park, Annals of Clinical and Laboratory Science (2015), reported improved cartilage histology after weekly intra-articular AOD-9604 in a rabbit osteoarthritis model; a single small efficacy study, not a safety study.
Animal tolerability sets a floor. Formal toxicology of injected AOD-9604 has not been published, and short rodent protocols do not test months of repeated use.
Community and vendor sources describe injection-site redness, swelling and tenderness, and occasional transient headache or fatigue in early use. These are uncontrolled, unblinded self-reports with no denominator, from material of unverified purity. They cannot establish incidence, causation or severity; they are hypotheses, not findings.
AOD-9604 does not bind the growth hormone receptor with measurable affinity, does not raise IGF-1, and its rodent effect survives β3-adrenergic-receptor knockout. No defined target has been identified, which cuts two ways for safety. The secretagogue-class concerns — IGF-1 elevation, insulin resistance, fluid retention — are not expected, and the trials did not find them; that describes what was measured, not a safety claim. But a compound with no known receptor has no known off-target profile either: there is no mechanism from which to predict what a different route, dose or duration might do. "Looked for and not found" and "not looked for" remain different statements, and most injectable questions fall in the second category.
Some share of any reaction reported with unregulated peptide use plausibly traces to the vial rather than the molecule: synthesis impurities, truncated sequences, residual solvents, endotoxin load, or material degraded by a broken cold chain. AOD-9604 adds a specific one: its two cysteines are joined by a disulfide bridge, and the oxidised and reduced forms have the same nominal sequence with masses two daltons apart, so a correctly labelled lot may still not be the species the trials used. A certificate of analysis reporting HPLC purity and a mass-spectrometry identity check is the only way to separate compound effects from product effects; the lab-testing page explains what Canada Peptides tests. Storage follows the cold-chain and shelf-life guide: lyophilised at 2–8 °C in the dark, reconstituted solutions refrigerated and used within weeks, no repeated freeze–thaw.
AOD-9604 has no Health Canada market authorisation and no Drug Identification Number; it has not been reviewed for safety or efficacy, and it is sold in Canada for research use only. In September 2023 the U.S. FDA placed AOD-9604 in category 2 of its evaluation of bulk substances for section 503A compounding, citing insufficient safety data for the compounded form — a determination not contradicted by the earlier GRAS self-affirmation for oral food use. The WADA Prohibited List names AOD-9604 under S2, so it is prohibited for tested athletes at all times. Research-grade material is listed here as AOD-9604 2.5MG.
Does AOD-9604 have a documented side-effect profile? For oral tablets over up to twelve weeks, yes: a pooled analysis of six trials in roughly nine hundred participants reported adverse events comparable to placebo and no metabolic or antibody signal. For injected material, no controlled human data exist.
Did the trials find effects on blood sugar or IGF-1? No. The pooled analysis reported no change in glucose or insulin and no rise in IGF-1 — the questions the trials were built to answer, because they are growth hormone's known liabilities.
Is AOD-9604 GRAS or FDA approved? Neither in the sense usually implied. A 2014 GRAS self-affirmation for low oral doses in foods was a company-panel determination, not an FDA approval. In 2023 the FDA separately declined to allow AOD-9604 in compounded medicines.
Why was development stopped if the safety data were good? Because the Phase 2b trial did not meet its primary weight-loss endpoint. The safety record survived the efficacy failure; the programme did not.
Is this medical advice? No. AOD-9604 is a research-grade material for laboratory use only, not for human or veterinary use. This page reports what published studies recorded; it is not a safety assurance, a dosing recommendation or a substitute for a licensed physician.
